Todd Asset Management LLC acquired a new stake in shares of Pfizer, Inc. (NYSE:PFE) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 600,025 shares of the biopharmaceutical company’s stock, valued at approximately $20,323,000.

A number of other institutional investors have also made changes to their positions in PFE. Nelson Roberts Investment Advisors LLC increased its position in shares of Pfizer by 6.7% in the second quarter. Nelson Roberts Investment Advisors LLC now owns 2,999 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 189 shares during the period. Tuttle Tactical Management LLC acquired a new position in shares of Pfizer during the second quarter valued at approximately $117,000. Cornerstone Advisors Inc. increased its position in shares of Pfizer by 17.4% in the third quarter. Cornerstone Advisors Inc. now owns 3,650 shares of the biopharmaceutical company’s stock valued at $124,000 after buying an additional 541 shares during the period. Gierl Augustine Investment Management Inc increased its position in shares of Pfizer by 5.8% in the third quarter. Gierl Augustine Investment Management Inc now owns 3,718 shares of the biopharmaceutical company’s stock valued at $126,000 after buying an additional 205 shares during the period. Finally, Delphi Private Advisors LLC increased its position in shares of Pfizer by 1.2% in the second quarter. Delphi Private Advisors LLC now owns 4,007 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 47 shares during the period. 68.39% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Shares of Pfizer, Inc. (NYSE:PFE) opened at 32.52 on Friday. The firm has a market capitalization of $197.34 billion, a price-to-earnings ratio of 32.65 and a beta of 0.91. The company’s 50-day moving average price is $32.41 and its 200 day moving average price is $33.71. Pfizer, Inc. has a 12-month low of $28.25 and a 12-month high of $37.39.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, November 1st. The biopharmaceutical company reported $0.61 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.62 by $0.01. The business had revenue of $13.05 billion for the quarter, compared to analyst estimates of $13.05 billion. Pfizer had a return on equity of 23.68% and a net margin of 13.09%. The company’s revenue was up 7.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.60 earnings per share. On average, equities research analysts forecast that Pfizer, Inc. will post $2.42 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 1st. Stockholders of record on Friday, February 3rd will be given a dividend of $0.32 per share. This is a boost from Pfizer’s previous quarterly dividend of $0.30. This represents a $1.28 annualized dividend and a dividend yield of 3.94%. The ex-dividend date of this dividend is Wednesday, February 1st. Pfizer’s dividend payout ratio is currently 106.20%.

COPYRIGHT VIOLATION NOTICE: This story was originally posted by Daily Political and is the propert of of Daily Political. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The correct version of this story can be viewed at http://www.dailypolitical.com/2017/01/14/todd-asset-management-llc-invests-20323000-in-pfizer-inc-pfe.html.

A number of equities analysts have recently issued reports on the company. BMO Capital Markets set a $33.00 price target on Pfizer and gave the stock a “hold” rating in a research report on Wednesday, November 30th. Vetr downgraded Pfizer from a “strong-buy” rating to a “buy” rating and set a $36.33 price target on the stock. in a research report on Monday, December 26th. Guggenheim assumed coverage on Pfizer in a research report on Friday, December 2nd. They set a “neutral” rating on the stock. Sanford C. Bernstein reissued an “overweight” rating on shares of Pfizer in a research report on Wednesday, December 7th. Finally, Jefferies Group set a $34.00 price target on Pfizer and gave the stock a “neutral” rating in a research report on Friday, November 11th. Twelve analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $37.30.

In other news, insider Anthony J. Maddaluna sold 10,000 shares of the business’s stock in a transaction dated Wednesday, November 9th. The stock was sold at an average price of $33.00, for a total value of $330,000.00. Following the completion of the sale, the insider now directly owns 112,087 shares of the company’s stock, valued at approximately $3,698,871. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Albert Bourla sold 18,390 shares of the business’s stock in a transaction dated Friday, November 4th. The shares were sold at an average price of $30.05, for a total value of $552,619.50. Following the completion of the sale, the insider now directly owns 149,199 shares of the company’s stock, valued at $4,483,429.95. The disclosure for this sale can be found here. Insiders own 0.07% of the company’s stock.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. The Company’s segments include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). Its biopharmaceutical products include Lipitor, Sutent and the Premarin family of products.

5 Day Chart for NYSE:PFE

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.